Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

1.

BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome.

Toon CW, Walsh MD, Chou A, Capper D, Clarkson A, Sioson L, Clarke S, Mead S, Walters RJ, Clendenning M, Rosty C, Young JP, Win AK, Hopper JL, Crook A, von Deimling A, Jenkins MA, Buchanan DD, Gill AJ.

Am J Surg Pathol. 2013 Oct;37(10):1592-602. doi: 10.1097/PAS.0b013e31828f233d.

2.

Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas.

Boissière-Michot F, Frugier H, Ho-Pun-Cheung A, Lopez-Crapez E, Duffour J, Bibeau F.

Virchows Arch. 2016 Aug;469(2):135-44. doi: 10.1007/s00428-016-1958-1. Epub 2016 May 25.

PMID:
27220764
3.

Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer.

Moreira L, Muñoz J, Cuatrecasas M, Quintanilla I, Leoz ML, Carballal S, Ocaña T, López-Cerón M, Pellise M, Castellví-Bel S, Jover R, Andreu M, Carracedo A, Xicola RM, Llor X, Boland CR, Goel A, Castells A, Balaguer F; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association.

Cancer. 2015 May 1;121(9):1395-404. doi: 10.1002/cncr.29190. Epub 2014 Dec 29.

4.

Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts.

Buchanan DD, Clendenning M, Rosty C, Eriksen SV, Walsh MD, Walters RJ, Thibodeau SN, Stewart J, Preston S, Win AK, Flander L, Ouakrim DA, Macrae FA, Boussioutas A, Winship IM, Giles GG, Hopper JL, Southey MC, English D, Jenkins MA.

J Gastroenterol Hepatol. 2017 Feb;32(2):427-438. doi: 10.1111/jgh.13468.

5.

Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification.

Parsons MT, Buchanan DD, Thompson B, Young JP, Spurdle AB.

J Med Genet. 2012 Mar;49(3):151-7. doi: 10.1136/jmedgenet-2011-100714. Review.

PMID:
22368298
6.

Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.

Cohen R, Buhard O, Cervera P, Hain E, Dumont S, Bardier A, Bachet JB, Gornet JM, Lopez-Trabada D, Dumont S, Kaci R, Bertheau P, Renaud F, Bibeau F, Parc Y, Vernerey D, Duval A, Svrcek M, André T.

Eur J Cancer. 2017 Nov;86:266-274. doi: 10.1016/j.ejca.2017.09.022. Epub 2017 Oct 19.

PMID:
29055842
7.

BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.

Capper D, Voigt A, Bozukova G, Ahadova A, Kickingereder P, von Deimling A, von Knebel Doeberitz M, Kloor M.

Int J Cancer. 2013 Oct 1;133(7):1624-30. doi: 10.1002/ijc.28183. Epub 2013 Apr 25.

8.

Screening for Lynch syndrome and referral to clinical genetics by selective mismatch repair protein immunohistochemistry testing: an audit and cost analysis.

Colling R, Church DN, Carmichael J, Murphy L, East J, Risby P, Kerr R, Chetty R, Wang LM.

J Clin Pathol. 2015 Dec;68(12):1036-9. doi: 10.1136/jclinpath-2015-203083. Epub 2015 Jul 22.

PMID:
26201544
9.

Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center.

Heald B, Plesec T, Liu X, Pai R, Patil D, Moline J, Sharp RR, Burke CA, Kalady MF, Church J, Eng C.

J Clin Oncol. 2013 Apr 1;31(10):1336-40. doi: 10.1200/JCO.2012.45.1674. Epub 2013 Feb 11.

10.

A state-wide population-based program for detection of lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours.

Schofield L, Grieu F, Goldblatt J, Amanuel B, Iacopetta B.

Fam Cancer. 2012 Mar;11(1):1-6. doi: 10.1007/s10689-011-9494-2.

PMID:
22120844
11.

BRAF mutation in sporadic colorectal cancer and Lynch syndrome.

Thiel A, Heinonen M, Kantonen J, Gylling A, Lahtinen L, Korhonen M, Kytölä S, Mecklin JP, Orpana A, Peltomäki P, Ristimäki A.

Virchows Arch. 2013 Nov;463(5):613-21. doi: 10.1007/s00428-013-1470-9. Epub 2013 Aug 21.

PMID:
23963522
12.

BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.

Molinari F, Signoroni S, Lampis A, Bertan C, Perrone F, Sala P, Mondini P, Crippa S, Bertario L, Frattini M.

Tumori. 2014 May-Jun;100(3):315-20. doi: 10.1700/1578.17214.

PMID:
25076244
13.

Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability.

Nakagawa H, Nagasaka T, Cullings HM, Notohara K, Hoshijima N, Young J, Lynch HT, Tanaka N, Matsubara N.

Oncol Rep. 2009 Jun;21(6):1577-83.

PMID:
19424639
14.

Population-based screening for Lynch syndrome in Western Australia.

Schofield L, Grieu F, Amanuel B, Carrello A, Spagnolo D, Kiraly C, Pachter N, Goldblatt J, Platell C, Levitt M, Stewart C, Salama P, Ee H, Raftopoulous S, Katris P, Threlfall T, Edkins E, Wallace M, Iacopetta B.

Int J Cancer. 2014 Sep 1;135(5):1085-91. doi: 10.1002/ijc.28744. Epub 2014 Feb 24.

15.

Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers.

Chang SC, Lin PC, Yang SH, Wang HS, Liang WY, Lin JK.

Surgery. 2010 May;147(5):720-8. doi: 10.1016/j.surg.2009.10.069. Epub 2009 Dec 31.

PMID:
20045164
16.

BRAF V600E mutation analysis simplifies the testing algorithm for Lynch syndrome.

Jin M, Hampel H, Zhou X, Schunemann L, Yearsley M, Frankel WL.

Am J Clin Pathol. 2013 Aug;140(2):177-83. doi: 10.1309/AJCPB9FOVH1HGKFR.

PMID:
23897252
17.

BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer.

Toon CW, Chou A, DeSilva K, Chan J, Patterson J, Clarkson A, Sioson L, Jankova L, Gill AJ.

Mod Pathol. 2014 May;27(5):644-50. doi: 10.1038/modpathol.2013.200. Epub 2013 Oct 25.

18.

Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.

Mills AM, Sloan EA, Thomas M, Modesitt SC, Stoler MH, Atkins KA, Moskaluk CA.

Am J Surg Pathol. 2016 Feb;40(2):155-65. doi: 10.1097/PAS.0000000000000544.

PMID:
26523542
19.

Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years.

Leenen CH, van Lier MG, van Doorn HC, van Leerdam ME, Kooi SG, de Waard J, Hoedemaeker RF, van den Ouweland AM, Hulspas SM, Dubbink HJ, Kuipers EJ, Wagner A, Dinjens WN, Steyerberg EW.

Gynecol Oncol. 2012 May;125(2):414-20. doi: 10.1016/j.ygyno.2012.01.049. Epub 2012 Feb 1.

PMID:
22306203
20.

A further investigation of combined mismatch repair and BRAFV600E mutation specific immunohistochemistry as a predictor of overall survival in colorectal carcinoma.

Luey N, Toon CW, Sioson L, Clarkson A, Watson N, Cussigh C, Kedziora A, Pincott S, Pillinger S, Evans J, Percy J, Engel A, Schnitzler M, Gill AJ.

PLoS One. 2014 Aug 25;9(8):e106105. doi: 10.1371/journal.pone.0106105. eCollection 2014.

Supplemental Content

Support Center